The New England Journal of Medicine published results from a study to test AstraZeneca’s vaccine’s efficacy for the South African variant of COVID-19. The clinical study was conducted in South Africa with 1,467 participants, of which 2.5% developed mild-to-moderate COVID-19 for at least 14 days after receiving the first and second dose, compared to 3.2% that became infected after taking the placebo. Of those who were infected, 93% were infected with the variant, and the study projected that the vaccine had a 10.9% efficacy rate against the variant.
Read more here.
More on: News Regulatory
Don’t miss the next article from HealthFirst 100.
Join our mailing list to receive the latest posts from our blog directly in your inbox.